OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Non-Small Cell Lung Cancer (NSCLC) Overview

Non-Small Cell Lung Cancer (NSCLC) — 46 Curated Clinical Trials

Registry Snapshot: 2026-11-10 · Table SHA-256: 4aa905b7a2d5693a

NCT IdentifierTitle & SponsorPhase / Status
NCT03175224APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics Inc.
PHASE2
RECRUITING
NCT03191149Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
PHASE2
RECRUITING
NCT03851445Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
SWOG Cancer Research Network
PHASE2/PHASE3
RECRUITING
NCT04410796Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Memorial Sloan Kettering Cancer Center
PHASE2
RECRUITING
NCT04486833Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Genprex, Inc.
PHASE1/PHASE2
RECRUITING
NCT04613596Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
PHASE2/PHASE3
RECRUITING
NCT05099172First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
PHASE1/PHASE2
RECRUITING
NCT05144698RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
PHASE1/PHASE2
RECRUITING
NCT05150691A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
PHASE1/PHASE2
RECRUITING
NCT05456256A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Lantern Pharma Inc.
PHASE2
RECRUITING
NCT05785741A Study of DB-1310 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
PHASE1/PHASE2
RECRUITING
NCT05920356A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
PHASE3
RECRUITING
NCT06010329A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Teligene US
PHASE2
RECRUITING
NCT06047379Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
PHASE1/PHASE2
RECRUITING
NCT06090266A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
PHASE1/PHASE2
RECRUITING
NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
PHASE2
RECRUITING
NCT06350097Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca
PHASE3
RECRUITING
NCT06449313Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Georgetown University
PHASE2
RECRUITING
NCT06495125Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
PHASE2
RECRUITING
NCT06582771A Study of Sotorasib in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
PHASE2
RECRUITING
NCT06618287A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Bristol-Myers Squibb
PHASE1/PHASE2
RECRUITING
NCT06667076A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Janssen Research & Development, LLC
PHASE2
RECRUITING
NCT06706076A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
BlossomHill Therapeutics
PHASE1/PHASE2
RECRUITING
NCT06745908Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
ImmunityBio, Inc.
PHASE3
RECRUITING
NCT06750185Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
BioNTech SE
PHASE1/PHASE2
RECRUITING
NCT06772623Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
AbbVie
PHASE1/PHASE2
RECRUITING
NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
PHASE1/PHASE2
RECRUITING
NCT06890598Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company
PHASE3
RECRUITING
NCT06899126Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Daiichi Sankyo
PHASE3
RECRUITING
NCT07020221A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
PHASE1/PHASE2
RECRUITING
NCT07037758A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
Amgen
PHASE1
RECRUITING
NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
PHASE2/PHASE3
RECRUITING
NCT07148128Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Auricula Biosciences Inc.
PHASE1/PHASE2
RECRUITING
NCT07154290A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
PHASE2
RECRUITING
NCT07154706Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.
PHASE3
RECRUITING
NCT07190248A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Merck Sharp & Dohme LLC
PHASE3
RECRUITING
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Merck Sharp & Dohme LLC
PHASE2
RECRUITING
NCT07287995A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Astellas Pharma Global Development, Inc.
PHASE1/PHASE2
RECRUITING
NCT07393555Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
PHASE2
RECRUITING
NCT07405190Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
Massachusetts General Hospital
PHASE2
RECRUITING
NCT07439094A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
PHASE1/PHASE2
RECRUITING
NCT07535437A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
PHASE1/PHASE2
RECRUITING
NCT07538804A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
PHASE1/PHASE2
RECRUITING
NCT07586202A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Janssen Research & Development, LLC
PHASE2
RECRUITING
NCT07777822Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Revolution Medicines, Inc.
PHASE3
RECRUITING
NCT07874490Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC
NYU Langone Health
PHASE2
RECRUITING